Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas
Andrew D.J. Pearson, Nathalie Gaspar, Katherine A. Janeway, et al.
European Journal of Cancer (2022) Vol. 173, pp. 71-90
Open Access | Times Cited: 18

Showing 18 citing articles:

Paediatric Strategy Forum for Medicinal Product Development in Diffuse Midline Gliomas in Children and Adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration
Andrew D.J. Pearson, Sabine Mueller, Mariella G. Filbin, et al.
European Journal of Cancer (2025) Vol. 217, pp. 115230-115230
Open Access | Times Cited: 1
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM
Anna-Elisa Heipertz, Kristian W. Pajtler, Elke Pfaff, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 13
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer
Andrew D.J. Pearson, Steven G. DuBois, Margaret E. Macy, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114145-114145
Closed Access | Times Cited: 4
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew D.J. Pearson, Sara M. Federico, Susanne A. Gatz, et al.
European Journal of Cancer (2023) Vol. 190, pp. 112950-112950
Open Access | Times Cited: 10
Multi‐Targeted Kinase Inhibitor Therapy in Pediatric Bone and Soft Tissue Sarcoma Patients—A Single Centre Experience
A. Mohas, Klára Horváth, Zsuzsanna Jakab, et al.
Cancer Medicine (2025) Vol. 14, Iss. 9
Open Access
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors
Andrew D.J. Pearson, Carl E. Allen, Jason Fangusaro, et al.
European Journal of Cancer (2022) Vol. 177, pp. 120-142
Open Access | Times Cited: 14
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102625-102625
Open Access | Times Cited: 6
Relationship between tumorigenesis, metastasis, immune evasion, and chemoresistance in osteosarcoma therapy
Yan Yik Lim, Ahmad Mujahid Ahmad Zaidi, Mainul Haque, et al.
Journal of Applied Pharmaceutical Science (2023)
Open Access | Times Cited: 5
ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?
Andrew D.J. Pearson, Teresa de Rojas, Dominik Karres, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 11, pp. 1354-1357
Closed Access | Times Cited: 8
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Nathalie Gaspar, Giun-Yi Hung, Sandra J. Strauss, et al.
JAMA Oncology (2024)
Open Access | Times Cited: 1
Stakeholder Perspectives on Randomized Clinical Trials for Children With Poor-Prognosis Cancers
Nick Bird, Nicole Scobie, Pablo Berlanga, et al.
JAMA Network Open (2024) Vol. 7, Iss. 12, pp. e2449239-e2449239
Closed Access | Times Cited: 1
Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development
Andrew D.J. Pearson, Teresa de Rojas, Dominik Karres, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 2, pp. 200-207
Open Access | Times Cited: 3
Paediatric drug development and evaluation: Existing challenges and recommendations
Florentia Kaguelidou, Maria Ouèdraogo, Jean‐Marc Tréluyer, et al.
Therapies (2022) Vol. 78, Iss. 1, pp. 105-114
Open Access | Times Cited: 5
Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance
Yan Yik Lim, Ahmad Mujahid Ahmad Zaidi, Mainul Haque, et al.
(2023)
Open Access | Times Cited: 2
Clinical research with targeted drugs in paediatric oncology
Paula Valle-Simón, Alberto M. Borobia, Antonio Pérez‐Martínez
Drug Discovery Today (2023) Vol. 28, Iss. 8, pp. 103672-103672
Closed Access | Times Cited: 2
Développement des médicaments en pédiatrie : défis existants et recommandations
Florentia Kaguelidou, Maria Ouèdraogo, Jean‐Marc Tréluyer, et al.
Therapies (2022) Vol. 78, Iss. 1, pp. 95-104
Open Access | Times Cited: 3
Policy of pediatric oncology drug development
Lenneke Schrier, C. Michel Zwaan, Carmelo Rizzari, et al.
Elsevier eBooks (2024), pp. 509-527
Closed Access
Dose Escalation in Pediatric Pelvic Ewing's Sarcoma: Insights from a National Training Initiative
G. Beldjoudi, F. Goudjil, Stéphanie Raucoules, et al.
(2024)
Closed Access
Page 1

Scroll to top